Top

Published in:

01-04-2021 | Giant Cell Arteritis | Review Article

Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs

Authors: Akhil Sood, Mukaila A. Raji

Published in: Clinical Rheumatology | Issue 4/2021

Abstract

Recent development of biologic disease-modifying anti-rheumatic drugs (DMARDs) has led to better control of disease activity among patients with chronic rheumatological diseases. Many patients with rheumatic disease are living longer, adding to the growing elderly population. Rheumatic diseases, most notably rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are known to increase the risk of cognitive impairment. Systemic inflammation associated with chronic rheumatological diseases has been postulated to be key driver of cognitive decline. Recent development of classic and biologic DMARDs have led to better control of disease activity among patients with rheumatic conditions. It is proposed that strict control of systemic inflammation will significantly lower the risk of cognitive impairment among patients with rheumatic disease. The impact of classic DMARDs on cognitive function appears to be variable. On the other hand, biologic DMARDs, specifically antitumor necrosis factor (TNF) drugs (i.e., etanercept), have been shown to significantly lower the risk of dementia. Experimental studies on IL-1, IL-6, and B and T cell blockade are promising. However, clinical data is limited. Preclinical studies on targeted therapies, specifically JAK/STAT inhibitors, also show promising results. Additional studies are necessary to better understand the impact of these newer biologic agents on cognitive function in elderly patients with rheumatic disease.

Key points

• Patients with chronic rheumatic conditions are beginning to live longer, adding to the elderly population.

• Patients with chronic rheumatologic disease are at increased risk of cognitive impairment compared to the general population.

• Recent development of biologic (i.e., TNF, IL-1, IL-6) and targeted drugs (i.e., Janus kinase inhibitors) have led to better control of disease activity.

• Current evidence suggests that TNF inhibitors may have beneficial effects on cognitive function. However, evidence on newer biologic and targeted therapies is limited.

Boonen A, van de Rest J, Dequeker J, van der Linden S (1997) How Renoir coped with rheumatoid arthritis. Bmj. 315(7123):1704–1708. https://doi.org/10.1136/bmj.315.7123.1704CrossRefPubMedPubMedCentral

Lahaye C, Tatar Z, Dubost JJ, Soubrier M (2015) Overview of biologic treatments in the elderly. Jt Bone Spine 82(3):154–160. https://doi.org/10.1016/j.jbspin.2014.10.012CrossRef

Hugo J, Ganguli M (2014) Dementia and cognitive impairment: epidemiology, diagnosis, and treatment clinics in geriatric medicine. Clin Geriatr Med 30(3):421–442. https://doi.org/10.1016/j.cger.2014.04.001CrossRefPubMedPubMedCentral

Shin SY, Katz P, Wallhagen M, Julian L (2012) Cognitive impairment in persons with rheumatoid arthritis. Arthritis Care Res 64(8):1144–1150. https://doi.org/10.1002/acr.21683CrossRef

Lee JH, Kim GT, Kim YK, Lee SG (2018) Cognitive function of patients with rheumatoid arthritis is associated with disease activity but not carotid atherosclerotic changes. Clin Exp Rheumatol 36(5):856–861PubMed

Murray SG, Yazdany J, Kaiser R, Criswell LA, Trupin L, Yelin EH, Katz PP, Julian LJ (2012) Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus. Arthritis Care Res 64(9):1328–1333. https://doi.org/10.1002/acr.21691CrossRef

Hanly JG, Hong C, Smith S, Fisk JD (1999) A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 42(4):728–734. https://doi.org/10.1002/1529-0131(199904)42:4<728::AID-ANR16>3.0.CO;2-OCrossRefPubMed

Jagpal A, Navarro-Millán I (2018) Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol 2(1):10. https://doi.org/10.1186/s41927-018-0014-yCrossRefPubMedPubMedCentral

Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52(3):722–732. https://doi.org/10.1002/art.20878CrossRefPubMed

10.

Liao KP, Solomon DH (2013) Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford, England) 52(1):45–52. https://doi.org/10.1093/rheumatology/kes243CrossRef

11.

Im CH, Kim NR, Kang JW, Kim JH, Kang JY, Bae GB, Nam EJ, Kang YM (2014) Inflammatory burden interacts with conventional cardiovascular risk factors for carotid plaque formation in rheumatoid arthritis. Rheumatology. 54(5):808–815. https://doi.org/10.1093/rheumatology/keu376CrossRefPubMed

12.

Ajeganova S, Andersson MLE, Frostegård J, Hafström I (2013) Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol 40(12):1958–1966. https://doi.org/10.3899/jrheum.130365CrossRefPubMed

13.

del Rincón I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48(7):1833–1840. https://doi.org/10.1002/art.11078CrossRefPubMed

14.

Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MRF, Raggi P, Stein CM (2003) Premature coronary-artery atherosclerosis in systemic lupus Erythematosus. N Engl J Med 349(25):2407–2415. https://doi.org/10.1056/NEJMoa035611CrossRefPubMed

15.

Schoenfeld SR, Kasturi S, Costenbader KH (2013) The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 43(1):77–95. https://doi.org/10.1016/j.semarthrit.2012.12.002CrossRefPubMed

16.

Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC (2013) Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 12(10):1004–1015. https://doi.org/10.1016/j.autrev.2013.03.013CrossRefPubMed

17.

Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, Greenlee RT (2014) Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol 41(4):680–687. https://doi.org/10.3899/jrheum.130874CrossRefPubMedPubMedCentral

18.

Wu G-C, Liu H-R, Leng R-X, Li X-P, Li X-M, Pan H-F, Ye DQ (2016) Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systemic review and meta-analysis. Autoimmun Rev 15(1):22–37. https://doi.org/10.1016/j.autrev.2015.10.002CrossRefPubMed

19.

Lin Y-R, Chou L-C, Chen H-C, Liou T-H, Huang S-W, Lin H-W (2016) Increased risk of dementia in patients with systemic lupus erythematosus: a nationwide population-based cohort study. Arthritis Care Res 68(12):1774–1779. https://doi.org/10.1002/acr.22914CrossRef

20.

Tomietto P, Annese V, D'Agostini S, Venturini P, La Torre G, De Vita S et al (2007) General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Care Res 57(8):1461–1472. https://doi.org/10.1002/art.23098CrossRef

21.

Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA (1999) A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 42(4):735–741. https://doi.org/10.1002/1529-0131(199904)42:4<735::AID-ANR17>3.0.CO;2-LCrossRefPubMed

22.

Gonzales-Portillo F, McIntyre JA, Wagenknecht DR, Williams LS, Bruno A, Biller J (2001) Spectrum of antiphospholipid antibodies (aPL) in patients with cerebrovascular disease. J Stroke Cerebrovasc Dis 10(5):222–226. https://doi.org/10.1053/jscd.2001.29818CrossRefPubMed

23.

Duarte-García A, Romero-Díaz J, Juárez S, Cicero-Casarrubias A, Fragoso-Loyo H, Núñez-Alvarez C et al (2018) Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with systemic lupus erythematosus and cognitive dysfunction. PLoS One 13(5):e0196487-e. https://doi.org/10.1371/journal.pone.0196487CrossRef

24.

Ungprasert P, Srivali N, Kittanamongkolchai W (2015) Risk of coronary artery disease in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Transl Med 3(4):51. https://doi.org/10.3978/j.issn.2305-5839.2015.02.05CrossRefPubMedPubMedCentral

25.

Peluso R, Caso F, Tasso M, Sabbatino V, Lupoli R, Dario Di Minno MN et al (2019) Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis. Open Access Rheumatol 11:143–156. https://doi.org/10.2147/OARRR.S206931CrossRefPubMedPubMedCentral

26.

Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer's Dement (New York, N Y) 4:575–590. https://doi.org/10.1016/j.trci.2018.06.014CrossRef

27.

Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S (2007) Inflammatory markers and the risk of Alzheimer disease. Neurology. 68(22):1902–1908. https://doi.org/10.1212/01.wnl.0000263217.36439.daCrossRefPubMed

28.

Petersen LE, Baptista TSA, Molina JK, Motta JG, do Prado A, Piovesan DM et al (2018) Cognitive impairment in rheumatoid arthritis: role of lymphocyte subsets, cytokines and neurotrophic factors. Clin Rheumatol 37(5):1171–1181. https://doi.org/10.1007/s10067-018-3990-9CrossRefPubMed

29.

Baptista TSA, Petersen LE, Molina JK, de Nardi T, Wieck A, do Prado A et al (2017) Autoantibodies against myelin sheath and S100β are associated with cognitive dysfunction in patients with rheumatoid arthritis. Clin Rheumatol 36(9):1959–1968. https://doi.org/10.1007/s10067-017-3724-4CrossRefPubMed

30.

Tobinick E, Gross H, Weinberger A, Cohen H (2006) TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed. 8(2):25PubMedPubMedCentral

31.

Tobinick EL, Gross H (2008a) Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflammation 5:2. https://doi.org/10.1186/1742-2094-5-2CrossRefPubMedPubMedCentral

32.

Tobinick EL, Gross H (2008b) Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol 8:27. https://doi.org/10.1186/1471-2377-8-27CrossRefPubMedPubMedCentral

33.

Butchart J, Brook L, Hopkins V, Teeling J, Püntener U, Culliford D et al (2015) Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 84(21):2161–2168. https://doi.org/10.1212/wnl.0000000000001617CrossRefPubMedPubMedCentral

34.

Chen K-T, Chen Y-C, Fan Y-H, Lin W-X, Lin W-C, Wang Y-H, Lin L, Chiou JY, Wei JCC (2018) Rheumatic diseases are associated with a higher risk of dementia: a nation-wide, population-based, case-control study. Int J Rheum Dis 21(2):373–380. https://doi.org/10.1111/1756-185x.13246CrossRefPubMed

35.

Meade T, Manolios N, Cumming SR, Conaghan PG, Katz P (2018) Cognitive impairment in rheumatoid arthritis: a systematic review. Arthritis Care Res 70(1):39–52. https://doi.org/10.1002/acr.23243CrossRef

36.

Vitturi BK, Nascimento BAC, Alves BR, de Campos FSC, Torigoe DY (2019) Cognitive impairment in patients with rheumatoid arthritis. J Clin Neurosci 69:81–87. https://doi.org/10.1016/j.jocn.2019.08.027CrossRefPubMed

37.

Ungprasert P, Wijarnpreecha K, Thongprayoon C (2016) Rheumatoid arthritis and the risk of dementia: a systematic review and meta-analysis. Neurol India 64(1):56–61. https://doi.org/10.4103/0028-3886.173623CrossRefPubMed

38.

Wallin K, Solomon A, Kåreholt I, Tuomilehto J, Soininen H, Kivipelto M (2012) Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-based study. J Alzheimers Dis 31:669–676. https://doi.org/10.3233/JAD-2012-111736CrossRefPubMed

39.

Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 58(8):1214–1220. https://doi.org/10.1212/wnl.58.8.1214CrossRefPubMed

40.

Kozora E, Arciniegas DB, Filley CM, West SG, Brown M, Miller D, Grimm A, Devore MD, Wingrove C, Zhang L (2008) Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. Arthritis Rheum 59(11):1639–1646. https://doi.org/10.1002/art.24189CrossRefPubMed

41.

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. (1999) Arthritis & Rheumatism. 42(4):599–608. https://doi.org/10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F

42.

Kozora E, Ellison MC, West S (2004) Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Care Res 51(5):810–818. https://doi.org/10.1002/art.20692CrossRef

43.

Rayes HA, Tani C, Kwan A, Marzouk S, Colosimo K, Medina-Rosas J, Mustafa A, Su J, Lambiris P, Mosca M, Touma Z (2018) What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Semin Arthritis Rheum 48(2):240–255. https://doi.org/10.1016/j.semarthrit.02.007CrossRefPubMed

44.

Leslie B, Crowe SF (2018) Cognitive functioning in systemic lupus erythematosus: a meta-analysis. Lupus. 27(6):920–929. https://doi.org/10.1177/0961203317751859CrossRefPubMed

45.

Cannerfelt B, Nystedt J, Jonsen A, Latt J, van Westen D, Lilja A et al (2018) White matter lesions and brain atrophy in systemic lupus erythematosus patients: correlation to cognitive dysfunction in a cohort of systemic lupus erythematosus patients using different definition models for neuropsychiatric systemic lupus erythematosus. Lupus. 27(7):1140–1149. https://doi.org/10.1177/0961203318763533CrossRefPubMed

46.

Conti F, Alessandri C, Perricone C, Scrivo R, Rezai S, Ceccarelli F et al (2012) Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS One 7(3):e33824-e. https://doi.org/10.1371/journal.pone.0033824CrossRef

47.

J Säve-Söderbergh, B E Malmvall, R Andersson, B A Bengtsson (1986) Giant cell arteritis as a cause of death. Report of nine cases. (0098–7484 (Print))

48.

Wilkinson IM, Russell RW (1972) Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol 27(5):378–391. https://doi.org/10.1001/archneur.1972.00490170010003CrossRefPubMed

49.

Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J (2005) Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 84(5):269–276. https://doi.org/10.1097/01.md.0000180042.42156.d1CrossRef

50.

Alsolaimani RS, Bhavsar SV, Khalidi NA, Pagnoux C, Mandzia JL, Tay K et al (2016) Severe intracranial involvement in giant cell arteritis: 5 cases and literature review. J Rheumatol. https://doi.org/10.3899/jrheum.150143

51.

Lariviere D, Sacre K, Klein I, Hyafil F, Choudat L, Chauveheid MP et al (2014) Extra- and intracranial cerebral vasculitis in giant cell arteritis: an observational study. Medicine (Baltimore) 93(28):e265. https://doi.org/10.1097/md.0000000000000265CrossRef

52.

Carlo MD, Becciolini A, Incorvaia A, Beci G, Biggioggero M, Favalli EG et al (2019) SAT0375 Mild cognitive impairment in psoriatic arthritis: prevalence and associated factors. Ann Rheum Dis 78(Suppl 2):1271. https://doi.org/10.1136/annrheumdis-2019-eular.4695CrossRef

53.

Marek-Józefowicz L, Jaracz M, Placek W, Czajkowski R, Borkowska A (2017) Cognitive impairment in patients with severe psoriasis. Postepy Dermatol Alergol 34(2):120–125. https://doi.org/10.5114/ada.2017.67074CrossRefPubMedPubMedCentral

54.

Gisondi P, Sala F, Alessandrini F, Avesani V, Zoccatelli G, Beltramello A, Moretto G, Gambina G, Girolomoni G (2014) Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology. 228(1):78–85. https://doi.org/10.1159/000357220CrossRefPubMed

55.

Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 163(3):586–592. https://doi.org/10.1111/j.1365-2133.2010.09941.xCrossRefPubMedPubMedCentral

56.

Campalani E, Allen MH, Fairhurst D, Young HS, Mendonca CO, Burden AD, Griffiths CEM, Crook MA, Barker JNWN, Smith CH (2006) Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 154(2):345–352. https://doi.org/10.1111/j.1365-2133.2005.06950.xCrossRefPubMed

57.

Mahley RW, Rall SC (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1(1):507–537. https://doi.org/10.1146/annurev.genom.1.1.507CrossRefPubMed

58.

Jiang H, Hampel H, Prvulovic D, Wallin A, Blennow K, Li R, Shen Y (2011) Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease. Mol Neurodegener 6:69. https://doi.org/10.1186/1750-1326-6-69CrossRefPubMedPubMedCentral

59.

Tobinick E (2009) Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. CNS Drugs 23(9):713–725. https://doi.org/10.2165/11310810-000000000-00000CrossRefPubMed

60.

Vitturi BK, Suriano ES, Pereira de Sousa AB, Torigoe DY (2020) Cognitive impairment in patients with ankylosing spondylitis. Can J Neurol Sci 47(2):219–225. https://doi.org/10.1017/cjn.2020.14CrossRefPubMed

61.

Baysal O, Durmus B, Ersoy Y, Altay Z, Senel K, Nas K et al (2011) Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. Rheumatol Int 31(6):795–800. https://doi.org/10.1007/s00296-010-1381-xCrossRefPubMed

62.

Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA (2006) Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford) 45(10):1288–1293. https://doi.org/10.1093/rheumatology/kel115CrossRef

63.

Jang HD, Park JS, Kim DW, Han K, Shin BJ, Lee JC, Choi SW, Suh SW, Yang JH, Park SY, Cho WJ, Hong JY (2019) Relationship between dementia and ankylosing spondylitis: a nationwide, population-based, retrospective longitudinal cohort study. PLoS One 14(1):e0210335. https://doi.org/10.1371/journal.pone.0210335CrossRefPubMedPubMedCentral

64.

Dautzenberg L, Jessurum N, Dautzenberg PLJ, Keijsers CJPW (2015) Reversible methotrexate-induced dementia: a case report. J Am Geriatr Soc 63(6):1273–1274. https://doi.org/10.1111/jgs.13517CrossRefPubMed

65.

Chou M-H, Wang J-Y, Lin C-L, Chung W-S (2017) DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: a propensity score-matched case–control study. Toxicol Appl Pharmacol 334:217–222. https://doi.org/10.1016/j.taap.2017.09.014CrossRefPubMed

66.

Judge A, Garriga C, Arden NK, Lovestone S, Prieto-Alhambra D, Cooper C, Edwards CJ (2017) Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimers Dement (N Y) 3(4):612–621. https://doi.org/10.1016/j.trci.2017.10.002CrossRef

67.

Newby D, Prieto-Alhambra D, Duarte-Salles T, Ansell D, Pedersen L, van der Lei J, Mosseveld M, Rijnbeek P, James G, Alexander M, Egger P, Podhorna J, Stewart R, Perera G, Avillach P, Grosdidier S, Lovestone S, Nevado-Holgado AJ (2020) Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. Alzheimers Res Ther 12(1):38. https://doi.org/10.1186/s13195-020-00606-5CrossRefPubMedPubMedCentral

68.

Fardet L, Nazareth I, Petersen I (2019) Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer’s disease: a population-based cohort study. Ann Rheum Dis 78(2):279–27282. https://doi.org/10.1136/annrheumdis-2018-214016CrossRefPubMed

69.

Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ (2001) Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 358(9280):455–460. https://doi.org/10.1016/s0140-6736(01)05623-9CrossRefPubMed

70.

Chou RC, Kane M, Ghimire S, Gautam S, Gui J (2016) Treatment for rheumatoid arthritis and risk of Alzheimer's disease: a nested case-control analysis. CNS Drugs 30(11):1111–1120. https://doi.org/10.1007/s40263-016-0374-zCrossRefPubMedPubMedCentral

71.

McGuinness B, Holmes C, Mirakhur A, Kearsley-Fleet L, Vieira R, Watson K, BSRBR-RA Contributors Group, BSRBR-RA Control Centre Consortium, Hyrich K (2018) The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBR-RA. Int J Geriatr Psychiatry 33(3):556–558. https://doi.org/10.1002/gps.4793CrossRefPubMed

72.

Zhou M, Xu R, Kaelber DC, Gurney ME (2020) Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis. PLoS One 15(3):e0229819. https://doi.org/10.1371/journal.pone.0229819

73.

McGuinness B (2018) Understanding whether drugs for rheumatoid arthritis can reduce the risk of Alzheimer’s disease. Alzheimer's Society. https://www.alzheimers.org.uk/research/our-research/research-projects/understanding-whether-drugs-rheumatoid-arthritis-can-reduce-risk-alzheimersdisease

74.

Hu J, Feng X, Valdearcos M, Lutrin D, Uchida Y, Koliwad SK, Maze M (2018) Interleukin-6 is both necessary and sufficient to produce perioperative neurocognitive disorder in mice. Br J Anaesth 120(3):537–545. https://doi.org/10.1016/j.bja.2017.11.096CrossRefPubMedPubMedCentral

75.

Elcioglu HK, Aslan E, Ahmad S, Alan S, Salva E, Elcioglu OH et al (2016) Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model. Mol Cell Biochem 420(1–2):21–28. https://doi.org/10.1007/s11010-016-2762-6CrossRefPubMed

76.

Kobayashi K, Okamoto Y, Inoue H, Usui T, Ihara M, Kawamata J, Miki Y, Mimori T, Tomimoto H, Takahashi R (2009) Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med 48(15):1307–1309. https://doi.org/10.2169/internalmedicine.48.1926CrossRefPubMed

77.

Yamaguchi Y, Furukawa K, Yamamoto T, Takahashi Y, Tanaka K, Takahashi M (2014) Multifocal encephalopathy and autoimmune-mediated limbic encephalitis following tocilizumab therapy. Intern Med 53(8):879–882. https://doi.org/10.2169/internalmedicine.53.0615CrossRefPubMed

78.

Bugatti S, Vitolo B, Caporali R, Montecucco C, Manzo A (2014) B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. Biomed Res Int 2014:681678–681614. https://doi.org/10.1155/2014/681678CrossRefPubMedPubMedCentral

79.

Cope AP, Schulze-Koops H, Aringer M (2007) The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol 25(5 Suppl 46):S4–S11PubMed

80.

Fuggle NR, Howe FA, Allen RL, Sofat N (2014) New insights into the impact of neuro-inflammation in rheumatoid arthritis. Front Neurosci 8:357. https://doi.org/10.3389/fnins.2014.00357CrossRefPubMedPubMedCentral

81.

Chang C, Zhao Y, Song G, She K (2018) Resveratrol protects hippocampal neurons against cerebral ischemia-reperfusion injury via modulating JAK/ERK/STAT signaling pathway in rats. J Neuroimmunol 315:9–14. https://doi.org/10.1016/j.jneuroim.2017.11.015CrossRefPubMed

82.

Ben Haim L, Ceyzeriat K, Carrillo-de Sauvage MA, Aubry F, Auregan G, Guillermier M, Ruiz M, Petit F, Houitte D, Faivre E, Vandesquille M, Aron-Badin R, Dhenain M, Deglon N, Hantraye P, Brouillet E, Bonvento G, Escartin C (2015) The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer’s and Huntington’s diseases. J Neurosci 35(6):2817–2829. https://doi.org/10.1523/jneurosci.3516-14.2015CrossRefPubMedPubMedCentral

83.

Cho S-K, Sung Y-K, Kim D, Won S, Choi C-B, Kim T-H et al (2016) Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskelet Disord 17:333. https://doi.org/10.1186/s12891-016-1185-6CrossRefPubMedPubMedCentral

84.

Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, Pallavicini FB, Caporali R, Gorla R (2010) Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol 38(2):90–96. https://doi.org/10.1007/s12016-009-8142-1CrossRefPubMed

85.

Borren NZ, Ananthakrishnan AN (2019) Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 17(9):1736–43.e4. https://doi.org/10.1016/j.cgh.2018.12.032CrossRefPubMedPubMedCentral

Title: Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs
Authors: Akhil Sood
Mukaila A. Raji
Publication date: 01-04-2021
Publisher: Springer International Publishing
Keywords: Giant Cell Arteritis
Systemic Lupus Erythematosus
Giant Cell Arteritis
Disease Modifying Anti-Rheumatic Drug
Alzheimer's Disease
Dementia
Ankylosing Spondylitis
Rheumatoid Arthritis
Alzheimer's Disease
Dementia
Published in: Clinical Rheumatology / Issue 4/2021
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05372-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Maintenance to target was associated with radiological outcomes in patients with rheumatoid arthritis: a real-world observational cohort study

Purpuric lip lesions in a young boy with IgA vasculitis

Combined diabetes and arthritis are associated with declined gait speed

Weighted gene co-expression network analysis identifies RHOH and TRAF1 as key candidate genes for psoriatic arthritis

Increasing of SIgA serum levels may reflect subclinical intestinal involvement in non-radiographic axial and peripheral spondyloarthritis

Cultural adaptation and validation of the Systemic Sclerosis Quality of Life questionnaire into Arabic language

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage